Evidence map›Paper›PMID 37834162›Full record

ReviewInternational journal of molecular sciences2023

Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer.

Tzu-Yi Chen, Meredith Mihalopoulos, Laura Zuluaga, Jordan Rich, Teja Ganta, Reza Mehrazin, Che-Kai Tsao, Ash Tewari, Edgar Gonzalez-Kozlova, Ketan Badani and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Tzu-Yi ChenDepartment of Pathology & Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Meredith MihalopoulosDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-9534-4740
Laura ZuluagaDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jordan RichDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-4434-5321
Teja GantaDepartment of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-2441-4104
Reza MehrazinDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Che-Kai TsaoDepartment of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ash TewariDepartment of Pathology & Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Edgar Gonzalez-KozlovaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ketan BadaniDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Navneet DograDepartment of Pathology & Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-4602-3991
Natasha KyprianouDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-8713-3599
Icahn School of Medicine at Mount Sinai · USTisch Hospital · US

Funding

Treatment-Induced Phenotypic Reprogramming in Prostate CancerR01CA232574 · NCI · UNIVERSITY OF KENTUCKY · PI KYPRIANOU, NATASHA · 2019 to 2023
$2.2M
Disparities in molecular testing among non-small cell lung cancer patientsP20CA264076 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENN, EMMA KATHERINE TARA · 2021 to 2024
$1.2M
Delineating the RNA cargo of exosomes from brain microenvironmentR21AG078848 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DOGRA, NAVNEET · 2022 to 2022
$464k
NCI NIH HHS P20 CA264076NCI NIH HHS R01 CA232574NIA NIH HHS R21 AG078848
6 · The paper itself

Abstract

Extracellular vesicles (EVs)-including apoptotic bodies, microvesicles, and exosomes-are released by almost all cell types and contain molecular footprints from their cell of origin, including lipids, proteins, metabolites, RNA, and DNA. They have been successfully isolated from blood, urine, semen, and other body fluids. In this review, we discuss the current understanding of the predictive value of EVs in prostate and renal cancer. We also describe the findings supporting the use of EVs from liquid biopsies in stratifying high-risk prostate/kidney cancer and advanced disease, such as castration-resistant (CRPC) and neuroendocrine prostate cancer (NEPC) as well as metastatic renal cell carcinoma (RCC). Assays based on EVs isolated from urine and blood have the potential to serve as highly sensitive diagnostic studies as well as predictive measures of tumor recurrence in patients with prostate and renal cancers. Overall, we discuss the biogenesis, isolation, liquid-biopsy, and therapeutic applications of EVs in CRPC, NEPC, and RCC.

Indexed as

Carcinoma, Renal CellExosomesExtracellular VesiclesKidney NeoplasmsProstatic Neoplasms, Castration-ResistantClinical RelevanceHumansMaleNeoplasm Recurrence, LocalProstateexosomesliquid biopsiespredictiontherapeutic targetingtumor progression

Identifiers

PMID37834162
PMCPMC10573190
OpenAlexW4387178947

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.